LeMaitre Vascular, Inc. (LMAT)

Market Cap	2.37B +14.4%
Revenue (ttm)	256.28M +13.3%
Net Income	62.40M +38.2%
EPS	2.72 +38.1%
Shares Out	22.85M
PE Ratio	39.69
Forward PE	35.09
Dividend	$1.00 (0.93%)
Ex-Dividend Date	May 21, 2026

Volume	139,341
Open	107.30
Previous Close	107.94
Day's Range	102.48 - 109.00
52-Week Range	78.35 - 118.01
Beta	0.60
Analysts	Buy
Price Target	112.60 (+8.7%)
Earnings Date	May 5, 2026

About LMAT

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheter...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Oct 19, 2006
• Employees: 655
• Stock Exchange: NASDAQ
• Ticker Symbol: LMAT
• Website: https://www.lemaitre.com

Financial Performance

In 2025, LeMaitre Vascular's revenue was $249.60 million, an increase of 13.53% compared to the previous year's $219.86 million. Earnings were $57.73 million, an increase of 31.10%.

Analyst Summary

According to 5 analysts, the average rating for LMAT stock is "Buy." The 12-month stock price target is $112.6, which is an increase of 8.70% from the latest price.

Price Target

$112.6

(8.70% upside)

Analyst Consensus: Buy